arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Surrozen, Inc./DE

SRZN
$25.49 ▲ +3.80 (+17.52%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
7 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
79
Health
Good
Bullish
auto_awesome

Analytical Summary

Surrozen, Inc./DE shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth -67.4%
Op. Margin None
ROIC 22.4%
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.48M
↓ -67.4%
Net Income Profit after all expenses
$-242.03M
↓ -280.8%
Operating Margin Operating profit as % of sales
-239.7%
↑ +32.4%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters